EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma

Leah A. Owen; Ashley A. Kowalewski; Stephen L. Lessnick

doi:10.1371/journal.pone.0001965

Loading metrics

Open Access

Peer-reviewed

Research Article

EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma

Leah A. Owen,

Affiliations Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, United States of America, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America
⨯
Ashley A. Kowalewski,

Affiliation Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, United States of America
⨯
Stephen L. Lessnick

*To whom correspondence should be addressed. E-mail: stephen.lessnick@hci.utah.edu

Affiliations Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, United States of America, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America, Center for Children, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America, Division of Pediatric Hematology/Oncology, University of Utah, Salt Lake City, Utah, United States of America
⨯

EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma

Leah A. Owen,
Ashley A. Kowalewski,
Stephen L. Lessnick

Published: April 16, 2008
https://doi.org/10.1371/journal.pone.0001965

About the Authors

Leah A. Owen

Ashley A. Kowalewski

Affiliation Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, United States of America

Stephen L. Lessnick

*To whom correspondence should be addressed. E-mail: stephen.lessnick@hci.utah.edu

Affiliations Department of Oncological Sciences, University of Utah, Salt Lake City, Utah, United States of America, School of Medicine, University of Utah, Salt Lake City, Utah, United States of America, Center for Children, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States of America, Division of Pediatric Hematology/Oncology, University of Utah, Salt Lake City, Utah, United States of America

Competing Interests

Dr. Lessnick owns stock in Merck, & Co. Merck supplied the vorinostat used in the study.

Author Contributions

Conceived and designed the experiments: SL LO. Performed the experiments: LO AK. Analyzed the data: SL LO AK. Wrote the paper: SL LO. Other: Supervised the project: SL.

Subject Areas
?

For more information about PLOS Subject Areas, click here.
We want your feedback. Do these Subject Areas make sense for this article? Click the target next to the incorrect Subject Area and let us know. Thanks for your help!

Ewing sarcoma
Is the Subject Area "Ewing sarcoma" applicable to this article?

Thanks for your feedback.
Carcinogenesis
Is the Subject Area "Carcinogenesis" applicable to this article?

Thanks for your feedback.
DNA transcription
Is the Subject Area "DNA transcription" applicable to this article?

Thanks for your feedback.
DNA-binding proteins
Is the Subject Area "DNA-binding proteins" applicable to this article?

Thanks for your feedback.
DNA binding assay
Is the Subject Area "DNA binding assay" applicable to this article?

Thanks for your feedback.
Microarrays
Is the Subject Area "Microarrays" applicable to this article?

Thanks for your feedback.
Cell fusion
Is the Subject Area "Cell fusion" applicable to this article?

Thanks for your feedback.
Gene regulation
Is the Subject Area "Gene regulation" applicable to this article?

Thanks for your feedback.